phosphotyrosine has been researched along with dactolisib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buet, D; Denis, N; Dusanter-Fourt, I; Gallais, I; Guillonneau, F; Guillouf, C; Kosmider, O; Lauret, E; Loew, D; Lombard, B; Mayeux, P; Moreau-Gachelin, F | 1 |
| Cho, E; Choi, KM; Chung, YH; Han, EH; Kang, M; Kim, B; Kim, E; Kim, JY; Shin, JH | 1 |
2 other study(ies) available for phosphotyrosine and dactolisib
| Article | Year |
|---|---|
Cotargeting signaling pathways driving survival and cell cycle circumvents resistance to Kit inhibitors in leukemia.
Topics: Adenylate Kinase; Animals; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Female; Humans; Imidazoles; Indoles; Leukemia, Mast-Cell; Mice; Mice, Nude; Mice, Transgenic; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Phosphotyrosine; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Proto-Oncogene Proteins c-kit; Pyrroles; Quinolines; RNA Interference; RNA, Small Interfering; Signal Transduction; STAT5 Transcription Factor; Tumor Stem Cell Assay | 2012 |
Prolonged MEK inhibition leads to acquired resistance and increased invasiveness in KRAS mutant gastric cancer.
Topics: Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; Humans; Imidazoles; Mitogen-Activated Protein Kinase Kinases; Mutation; Neoplasm Invasiveness; Niacinamide; Phenotype; Phosphatidylinositol 3-Kinases; Phosphorylation; Phosphotyrosine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); Quinolines; Stomach Neoplasms; TOR Serine-Threonine Kinases | 2018 |